Home / 2021 / February / 10

Daily Archives: February 10, 2021

Allterco Robotics Delivers Next Gen Shelly Motion Sensor Optimized with Silicon Labs Wi-Fi Technology

New motion sensor features market-leading battery performance and simplifies consumer experience in the smart home

Shelly Motion Sensor

Allterco Robotics Delivers Next Gen Shelly Motion Sensor Optimized with Silicon Labs Wi-FI Technology

SOFIA, Bulgaria and AUSTIN, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) — Allterco (BSE: A4L), makers of the IoT brand Shelly, and Silicon Labs (NASDAQ: SLAB), a leading provider of silicon, software and solutions for a smarter, more connected world, today introduce Shelly Motion, a next-generation motion sensor with unrivaled battery life enabled by Silicon Labs’ Wi-Fi IoT solution. Shelly Motion is the first product to combine Shelly’s innovative home automation sensors with the only industry-leading Wi-Fi solution designed to meet the ultra-low power requirements of IoT sensors. Optimized with Silicon Labs’ Wi-Fi technology, Shelly Motion is the most responsive, energy efficient, and easy-to-use smart home Wi-Fi motion sensor on the market today.

As consumers spend more time at home, they are increasingly looking for innovative smart home products that ensure a safer, efficient and more comfortable lifestyle. Shelly Motion, the latest in Shelly’s revolutionary Wi-Fi product line, empowers customers to connect directly to any Wi-Fi router without the use of a dedicated hub. The sensor also offers full compatibility with Alexa, Home Assistant, SmartThings, and other third-party home automation platforms for the ultimate ease of use.

Shelly Motion features a 6500 mAh rechargeable battery that can operate and remain connected to a home Wi-Fi network for more than one year on a single charge, unlike competing sensors that require a replacement battery or recharge after weeks of continuous operation. The sensor remains connected to the Wi-Fi network 24/7, delivering extremely quick real-time response (less than 200 ms on average) and instant detection of even the slightest movement. This combination of features delivers superior home automation experiences whereby Shelly Motion can trigger immediate action by another device, such as turning on the lights when a person enters a room.

“Shelly Motion integrates locally with Home Assistant without requiring a hub or any other hardware. The sensor’s permanent connection reduces system latency and thereby enhances consumer experience in the smart home,” said Paulus Schoutsen, founder, Home Assistant. “With Shelly Motion you’re going to have an easy to install and configure motion sensor with a battery that will last.”

In addition to the ultra-long battery life, key features of Shelly Motion include:

  • Real-Time Response: With quick motion detection capability, in less than 200ms – or as fast as the blink of an eye – the sensor can trigger action to any connected device, such as turning on the air-conditioner or opening room window shutters.
  • Unmatched Sensitivity: The unique 256 levels of sensitivity will allow you to adjust extremely precisely the distance and the movement to which the sensor reacts.
  • Tamper Detection: With 128 levels of vibration sensitivity, Shelly Motion will immediately inform homeowners if someone touches the device or tries to dislocate or move it from its initial position.
  • No Hub Required: Shelly Motion can be controlled directly without using a hub and is compatible with any standard Wi-Fi router.
  • Customized Schedule: Homeowners can customize sensors’ actions, like controlling other devices, based on days, hour, light intensity, sunset and sunrise or any defined personal preferences.

“We are thrilled to partner with Silicon Labs and introduce Shelly Motion to the market,” said Dimitar Dimitrov, CEO of Allterco. “Our first Wi-Fi motion sensor combines the powerful, yet easy to use features customers have come to expect from Shelly products combined with the cutting edge IoT technology from Silicon Labs. We are committed to working with the best in the industry to deliver accessible, proven smart home products and look forward to announcing more innovations with Silicon Labs in the months to come.”

“The new Shelly Motion Wi-Fi sensor meets the increasing need for low maintenance, long battery life operation from IoT products,” said Jake Alamat, VP and GM of IoT home and consumer products at Silicon Labs. “Silicon Labs’ market leading ultra-low power Wi-Fi IoT solutions play a key role in delivering superior performance and ease of use, simplifying the smart home experience.”

Shelly Motion will be available for sale at for $39.90/€33.25 (excluding tax). Additional product information is available HERE. To purchase visit http://shopusa.shelly.cloud or to shop the full line of Shelly products visit http://shelly.cloud.

About Allterco and Shelly

Allterco (BSE: A4L) is a leading IoT European company founded in Bulgaria, Europe. Providing high class home automation solutions is Allterco’s IoT brand Shelly. From concept to implementation and design to hardware, the products combine latest technology with modern design and user-friendly interface. Shelly’s leading technological solutions for home and office automation shape the smart home industry thanks to innovative ideas and advanced approach. shelly.cloud

Connect with Allterco:
Contact Allterco PR & Marketing team at marketing@allterco.com.

About Silicon Labs
Silicon Labs (NASDAQ: SLAB) is a leading provider of silicon, software and solutions for a smarter, more connected world. Our award-winning technologies are shaping the future of the Internet of Things, Internet infrastructure, industrial automation, consumer and automotive markets. Our world-class engineering team creates products focused on performance, energy savings, connectivity and simplicity. silabs.com

Connect with Silicon Labs
Contact Silicon Labs PR team at pr@silabs.com.

Cautionary Language
This press release may contain forward-looking statements based on Silicon Labs’ current expectations. These forward-looking statements involve risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements. For a discussion of factors that could impact Silicon Labs’ financial results and cause actual results to differ materially from those in the forward-looking statements, please refer to Silicon Labs’ filings with the SEC. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Note to editors: Silicon Labs, Silicon Laboratories, the “S” symbol, the Silicon Laboratories logo and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9919e5fb-db19-4219-858d-8ac4039b76e9

 

REMINDER: Bombardier to Report Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021

MONTRÉAL, Feb. 10, 2021 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 11, 2021.

On February 11, 2021 at 8:00 a.m., EST, Bombardier will hold a webcast/conference call intended for investors and financial analysts to review the company’s financial results for the fourth quarter ended December 31, 2020 and full year 2020 results.

A live webcast of the call and relevant financial charts will be available at http://ir.bombardier.com.

Stakeholders wishing to listen to the presentation and question and answer period by telephone may dial one of the following conference call numbers:

In English: 514-392-1587, passcode: 3221229# or
1-877-395-0279, passcode: 3221229# (toll-free in North America)
+800 4222 8835, passcode: 3221229# (overseas calls)
In French: (with translation) 514-861-1381, passcode: 5935392# or
1-877-695-6175, passcode: 5935392# (toll-free in North America)
+800 4222 8835, passcode: 5935392# (overseas calls)

The replay of this call will be available on Bombardier’s website shortly after the end of the webcast.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game-changing planes. Our products and services provide world-class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montréal, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of approximately 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.

Bombardier is a trademark of Bombardier Inc.

For Information

Jessica McDonald
Media Relations and Public Affairs
Bombardier Inc.
+1 514 262 7255

Nikkiso Clean Energy & Industrial Gases Group’s Pump Unit Acquires Intellectual Property to Manufacture Electric Mechanical Actuators

TEMECULA, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (CE&IG), a subsidiary of Nikkiso Co., Ltd (Japan), announces their Pump Unit has acquired the intellectual property (IP) to manufacture and assemble electric-mechanical actuators (EMA) and the associated control panels.

The high force EMA coupled to a cryogenic reciprocating pump eliminates the need for a gearbox and crankcase, which provides a compact layout for vertical submerged pump design. The EMA also provides complete control of the reciprocating pump’s piston speed and position, allowing for a wider turndown range, pulsation-free operation for multiple unit arrangements, and enhanced reliability.

CE&IG’s Pump Unit’s EMA actuated pumps have been in various phases of testing for the last four years including actual operation in a prototype hydrogen fueling station. The EMA actuated reciprocating pump is immediately available for hydrogen applications that require up to 900 Barg discharge pressure. High pressure LNG fuel supply pumps for marine industry applications will be available in the near future.

“This is an exciting next step for our Group and a significant benefit for our customers. CE&IG will now be able to manufacture the complete pump assembly (from cryogenic head to the drive unit) and provide our customers with a complete factory supported solution,” according to Peter Wagner, CEO of Cryogenic Industries and President of the Group.

With the IP acquisition, CE&IG’s Pump Unit will manufacture and assemble the EMAs at its Nikkiso ACD factory in Santa Ana, California.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information please visit www.cryoind.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19

  • Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19
  • More than 250,000 doses manufactured throughout Q1 2021; up to 1 million doses by mid-2021
  • FDA authorizes shortened infusion time for this neutralizing antibody therapy authorized for emergency use

SHANGHAI, China, Feb. 10, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for investigational etesevimab (JS016 or LY-CoV016) 1400 mg and bamlanivimab (LY-CoV555) 700 mg together, according to the company’s global partner Eli Lilly and Company (NYSE: LLY). This therapy is authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization. Etesevimab and bamlanivimab should be administered together via a single intravenous infusion as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.

In addition, the FDA has authorized infusion times for bamlanivimab alone and bamlanivimab and etesevimab together to be as short as 16 or 21 minutes, respectively – a significant reduction from the previously authorized time of 60 minutes. This change has been made in response to feedback received from front-line nurses and doctors administering these infusions and is aimed at reducing the burden on the healthcare system.

The EUA is based on Phase 3 data from the BLAZE-1 trial, announced on January 26, 2021, which demonstrated that etesevimab and bamlanivimab together reduced the risk of COVID-19 hospitalizations and death by 70 percent. These data replicate earlier results, published in The Journal of the American Medical Association (IF=45.54), in a much larger group of patients. The most common adverse event more often reported for patients receiving etesevimab and bamlanivimab together versus placebo was nausea on the day of infusion.

While Phase 2 and Phase 3 trials evaluated a range of doses of bamlanivimab alone and etesevimab and bamlanivimab together, data demonstrated consistent and similar clinical effects among all doses studied. Additionally, initial results from an ongoing Phase 2 study provided viral load and pharmacodynamic/pharmacokinetic data which demonstrated etesevimab 1400 mg and bamlanivimab 700 mg together produced similar effects to those observed in the Phase 3 trial with etesevimab 2800 and bamlanivimab 2800 together. Together, these data provide confidence in the authorized dose, which expands available supply to help more patients without sacrificing potential efficacy.

The FDA grants EUA to provide availability of a medicine that may help diagnose, treat or prevent a life-threatening disease when no adequate and approved alternatives are available. This administration of etesevimab and bamlanivimab together is authorized only for the duration of the declaration, unless the authorization is terminated or revoked sooner. The authorization is temporary and does not replace the formal review and approval process. The administration of etesevimab and bamlanivimab together remains investigational and has not been approved under a Biologics License Application (BLA). Evaluation of its safety and efficacy is ongoing in clinical trials. Data from these studies will be used to support a future BLA submission for the treatment.

Bamlanivimab alone is authorized in numerous countries, while bamlanivimab and etesevimab together is currently authorized in the U.S. and Italy. Lilly will continue working with global regulators to make these therapies available around the world. In an effort to help as many patients as possible, Lilly will continue to accelerate manufacturing of etesevimab for use around the world. Lilly, in collaboration with Amgen, plans to manufacture up to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021. There are 100,000 doses ready immediately and an additional 150,000 doses will be available throughout the first quarter. Lilly anticipates procurement and allocation of etesevimab and bamlanivimab together will mirror the process followed for bamlanivimab alone – making the therapy available directly to governments for allocation based on unmet needs. Global allocation will aim to ensure access for patients with high unmet need, no matter where they live.

Dr. Ning LI, CEO of Junshi Biosciences said: “Since the outbreak of the pandemic, Junshi Biosciences and the IMCAS have been dedicated to the co-development of neutralizing antibodies. Now, with Lilly, our global partner’s participation, the innovative therapy is authorized for use in the U.S. and Italy, while unremitting endeavors to meet the extensive anti-COVID-19 needs are made by the local and overseas medical industry. The data of etesevimab and bamlanivimab together provides strong evidence for the safety and efficacy of JS016, thus giving us confidence to proceed with the clinical trial of JS016, which is ongoing in several countries and regions, including Mainland China, Hong Kong, the Philippines, etc.”

About etesevimab(JS016)
Etesevimab (JS016 or LY-CoV016) is a recombinant fully human monoclonal neutralizing antibody, which specifically binds to the SARS-CoV-2 surface spike protein receptor binding domain with high affinity and can block the binding of the virus to the ACE2 host cell surface receptor. Point mutations were introduced into the native human IgG1 antibody to mitigate effector function. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology, Chinese Academy of Science (IMCAS). Junshi Biosciences leads development in Greater China, while Lilly leads development in the rest of the world.

Lilly has successfully completed a Phase 1 study (NCT04441931) of etesevimab in healthy U.S. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity. A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. Junshi Biosciences has completed a similar Phase 1 study in healthy volunteers in China and has initiated Phase 1b/2 trials in COVID-19 patients globally.

About bamlanivimab(LY-CoV555)
Bamlanivimab (LY-CoV555) is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

About BLAZE-1
BLAZE-1 (NCT04427501) is a randomized, double-blind, placebo-controlled Phase 2/3 study designed to assess the efficacy and safety of bamlanivimab alone or together with etesevimab for the treatment of symptomatic COVID-19 in the outpatient setting. To be eligible, patients were required to have mild or moderate symptoms of COVID-19 as well as a positive SARS-CoV-2 test based on a sample collected no more than three days prior to drug infusion.

In the Phase 2 portion of BLAZE-1, cohorts of mild to moderate, recently diagnosed COVID-19 patients, were randomized to one of three doses of bamlanivimab (700 mg, 2800 mg, and 7000 mg), etesevimab 2800 mg plus bamlanivimab 2800 mg, or placebo. Results from the Phase 2 cohorts of BLAZE-1 were published in the New England Journal of Medicine and The Journal of the American Medical Association.

In the Phase 3 portion of BLAZE-1, the combination therapy arms enrolled mild to moderate, recently diagnosed COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization, studying etesevimab 2800 mg plus bamlanivimab 2800 mg versus placebo. The primary outcome measure for the Phase 3 portion of the BLAZE-1 trial was the percentage of participants who experience COVID-related hospitalizations or death from any cause by day 29. The key secondary endpoints were change from baseline to day 7 in SARS-CoV-2 viral load, persistently high SARS-CoV-2 viral load on day 7, time to sustained symptom resolution, and COVID-related hospitalization, ER visit or death from any cause from baseline by day 29. Additional endpoints include change from baseline in viral load at other time points, symptom improvement, symptom resolution, as well as safety.

The study is ongoing with additional treatment arms. Across all treatment arms, the trial will enroll up to 3,300 participants.

About BLAZE-4
BLAZE-4 (NCT04634409) is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of bamlanivimab alone, and bamlanivimab and etesevimab together, at various doses, versus placebo for the treatment of symptomatic COVID-19 in the outpatient setting. Across all treatment arms, the trial will enroll an estimated 1,000 participants in the United States and Puerto Rico.

The primary outcome measure is percentage of participants who have a viral load greater than 5.27 at day 7. Additional endpoints include change from baseline to Day 7 in SARS-CoV-2 viral load, percentage of participants who experience COVID-related hospitalization, ER visit or death from baseline through Day 29, as well as safety.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016, China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/news. P-LLY

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

IFG ยุติคดีละเมิดทรัพย์สินทางปัญญาในแอฟริกาใต้สำเร็จ

เบเกอร์สฟีลด์, แคลิฟอร์เนีย, Feb. 10, 2021 (GLOBE NEWSWIRE) — INTERNATIONAL FRUIT GENETICS LLC (IFG) หลังจากการฟ้องร้องที่รุนแรงในช่วงหลายปี ในที่สุด IFG ก็ยุติการดำเนินคดีละเมิดซึ่งพยายามปกป้องพันธุ์องุ่นที่เป็นกรรมสิทธิ์ของตนใน Western Cape ประเทศแอฟริกาใต้

ในช่วงปี 2010 IFG ได้สรุปข้อตกลงการออกใบอนุญาต การปลูก และการทำการตลาดกับผู้ปลูกองุ่นบริโภคผลสดในเมือง Paarl ประเทศแอฟริกาใต้ รวมถึงหน่วยงานด้านเกษตรกรรมอื่นๆ ที่เกี่ยวข้อง ในแง่ของข้อตกลง ผู้เพาะปลูกได้รับอนุญาตให้ทำการปลูก เลี้ยงดู และทำการตลาดองุ่นพันธุ์ IFG หลายสายพันธุ์ในแอฟริกาใต้ ซึ่งประสบความสำเร็จเป็นเวลาหลายปี อย่างไรก็ตาม ในระหว่างการตรวจสอบ IFG ระบุว่าผู้เพาะปลูกรายนี้ได้ขยายบางสายพันธุ์เกินขอบเขตใบอนุญาตอย่างผิดกฎหมายและทำการเพาะปลูกและขยายสายพันธุ์ IFG ก่อนที่จะได้รับการคุ้มครองพันธุ์ในแอฟริกาใต้ จากการตรวจสอบเพิ่มเติม IFG ระบุว่าผู้เพาะปลูกได้ขโมยใบพันธุ์จากไร่องุ่นของหนึ่งในผู้ก่อตั้ง IFG ในแคลิฟอร์เนียขณะที่กำลังเยี่ยมชมและได้ขนส่งไปยังแอฟริกาใต้ ซึ่งมีการต่อกิ่ง ขยายพันธุ์ และเพาะปลูกในเชิงพาณิชย์

เนื่องจากการกระทำที่ผิดกฎหมายของผู้เพาะปลูก IFG จึงยกเลิกข้อตกลงทั้งหมดที่มีกับผู้ได้รับใบอนุญาตและขอให้ผู้เพาะปลูกยุติการใช้วัสดุสำหรับการเพาะปลูกที่เป็นกรรมสิทธิ์ของ IFG ทั้งหมดและให้ทำลายวัสดุสำหรับการเพาะปลูกที่เป็นกรรมสิทธิ์ IFG ทั้งหมดโดยการตัดเถาองุ่นทั้งหมดที่อยู่ใต้การต่อกิ่ง โชคไม่ดีที่ผู้เพาะปลูกปฏิเสธที่จะทำตามคำขอนั้น ส่งผลให้ IFG ต้องใช้มาตรการที่รุนแรงมากขึ้น รวมถึงการอายัดบัญชีธนาคารและการพิจารณาคดีในศาลเนื่องจากไม่ปฏิบัติตามคำสั่งของศาล

ท้ายที่สุด เมื่อเป็นที่ชัดเจนสำหรับผู้เพาะปลูกว่า IFG กำลังดำเนินการตามขั้นตอนที่จำเป็นเพื่อปกป้องทรัพย์สินทางปัญญาของตน ผู้เพาะปลูกได้ยอมรับและปฏิบัติตามโดยการตัดเถาองุ่นที่อยู่ด้านล่างของการต่อกิ่งสายพันธุ์ IFG ทั้งหมด

กรณีนี้นับเป็นความสำเร็จที่น่าทึ่งสำหรับ IFG และสำหรับเจ้าของสิทธิ์ของนักปรับปรุงพันธุ์พืช ซึ่งเป็นทรัพย์สินทางปัญญารูปแบบหนึ่งที่มีคุณค่ายิ่ง การเคารพสิทธิ์เหล่านี้ช่วยให้นักปรับปรุงพันธุ์พืชทั่วโลกสามารถลงทุนอย่างต่อเนื่อง เพื่อให้แน่ใจว่าอุตสาหกรรมองุ่นบริโภคสดจะมีอนาคตที่สดใสและมีชีวิตชีวา

“คดีนี้ยืดเยื้อมานานมาก และเราก็ดีใจที่มันสิ้นสุดลง ซึ่งเราไม่รู้สึกเสียดายอะไรเลย” Andy Higgins, CEO ของ IFG กล่าว “สิทธิ์ในทรัพย์สินทางปัญญาของเราเป็นหัวใจสำคัญของธุรกิจ และเราจำเป็นต้องปกป้องสิทธิ์นั้น เราจะไม่ลังเลที่จะดำเนินการในลักษณะเดียวกันนี้ในส่วนอื่นๆ ของโลกหากจำเป็นต้องทำ”

สำหรับข้อมูลเพิ่มเติม โปรดไปที่ www.ifg.world

ติดต่อด้านสื่อ:

Olivia Riley
Bastion Elevate
949-522-0549
olivia@bastionelevate.com

CNY: Face-to-face meetings with prison inmates not allowed

Face-to-face meetings between prison inmates and their family members in conjunction with Chinese New Year celebration will not be allowed at all prison institutions nationwide.

The Prisons Department in a statement said, however, a prepaid telephone calling facility would be provided as an alternative method to get in touch.

“The consideration was made as a measure to prevent the spread of COVID-19, and members of the public with any queries may refer to the relevant prison institution,” read the statement.

Source: BERNAMA News Agency

Farid Kamil, Boy Iman stripped of their ‘Datuk’ titles

The Pahang palace has revoked the ‘Datuk’ title held by five individuals including actors Farid Kamil Zahari and ‘Boy Iman’, or Noruliman A.Rahman.

State Secretary Datuk Seri Dr Sallehuddin Ishak who is also the state Registrar of Awards said the order was issued by the Sultan of Pahang Al-Sultan Abdullah Ri’ayatuddin Al-Mustafa Billah Shah, and the letters of withdrawal came into effect Feb 1.

Local businessmen Wong Shee Kai @ Ricky and Syed Mohammad Faiz Syed Azemman, and Vietnamese businesswoman Tran Thi Mai @ Maimunah were the other three whose titles were revoked.

The withdrawal letters for Wong and Tran Thi Mai were also effective Feb 1, while Syed Mohammad Faiz’s letter was effective Nov 12, 2020.

The five had previously been bestowed with the Darjah Indera Mahkota Pahang (DIMP) award which carries the title of Datuk.

“The nominees are not allowed to use any title bestowed previously and must return the award to the Pahang State Secretary’s Office,” he said in a statement here today.

No reason was given for the revocation of the titles, however, it is understood that all the individuals involved have been prosecuted in court for various offences.

Wong, who is also the founder of a company, is also listed as a wanted person in connection with offences under the Anti-Money Laundering, Anti-Terrorism Financing and Proceeds of Unlawful Activities Act 2001.

On Aug 18, 2019, the Pahang state government announced several reforms to the awarding of medals and state degrees, which among others, states that an immediate investigation should be made into recipients of awards associated with misconduct, dishonesty, or lack of integrity.

Source: BERNAMA News Agency